Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Array BioPharma Articles

Oncothyreon and Array collaborate on anti-HER2 compound ARRY-380

30 May 2013

Selumetinib is first drug to help patients with recurrent low-grade ovarian cancer

11 February 2013

First success of selumetinib, a targeted therapy in most common NSCLC

29 November 2012

Array BioPharma presents encouraging Ph II selumetinib results in ovarian cancer

5 April 2012

Array BioPharma set to earn up to $467 million from oncology deal with Novartis

20 April 2010

Showing 1-5 of 5 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Elan puts up formal "for sale" notice
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Elan puts up formal "for sale" notice
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS